Ryan Cross
@scienceboss.bsky.social
Senior Science Correspondent at Endpoints News. Reach out privately on Signal: RyanCross.25
InduPro, a startup founded by former Merck scientists who invented MicroMapping—a way to identify protein interactions—has struck a partnership with Eli Lilly worth up to $950M to develop 3 bispecific or trispecific cancer drugs. More in my exclusive for @endpts.com: endpoints.news/lilly-partne...
Exclusive: Lilly partners with protein mapping startup InduPro for up to $950M
InduPro Therapeutics partners with Eli Lilly on cancer drug development worth up to $950M, using MicroMapping tech to create bispecific antibodies, following recent Sanofi deal.
endpoints.news
January 7, 2026 at 2:47 PM
InduPro, a startup founded by former Merck scientists who invented MicroMapping—a way to identify protein interactions—has struck a partnership with Eli Lilly worth up to $950M to develop 3 bispecific or trispecific cancer drugs. More in my exclusive for @endpts.com: endpoints.news/lilly-partne...
The gene editing toolbox has exploded since CRISPR was invented, with each new tool promising to be better than the last.
Read my third deep and final deep dive of 2025 on the #CRISPR gene editing field's growing pains in @endpts.com
endpoints.news/as-gene-edit...
Read my third deep and final deep dive of 2025 on the #CRISPR gene editing field's growing pains in @endpts.com
endpoints.news/as-gene-edit...
Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures
Former Intellia scientist John Finn reflects on gene editing's evolution and the closure of Tome Biosciences, highlighting the industry's focus on tools over medicines.
endpoints.news
January 5, 2026 at 6:58 PM
The gene editing toolbox has exploded since CRISPR was invented, with each new tool promising to be better than the last.
Read my third deep and final deep dive of 2025 on the #CRISPR gene editing field's growing pains in @endpts.com
endpoints.news/as-gene-edit...
Read my third deep and final deep dive of 2025 on the #CRISPR gene editing field's growing pains in @endpts.com
endpoints.news/as-gene-edit...
Addition Therapeutics raises $106.5M for all-RNA (no DNA required) gene insertion therapies based on retrotransposons, aka 'jumping genes'
Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for @endpts.com has the details: endpoints.news/addition-the...
Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for @endpts.com has the details: endpoints.news/addition-the...
Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies
Addition Therapeutics has raised $106.5 million for a new way to install therapeutic genes in the human genome.
endpoints.news
December 17, 2025 at 1:44 PM
Addition Therapeutics raises $106.5M for all-RNA (no DNA required) gene insertion therapies based on retrotransposons, aka 'jumping genes'
Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for @endpts.com has the details: endpoints.news/addition-the...
Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for @endpts.com has the details: endpoints.news/addition-the...
Western drugmakers are increasingly turning to Chinese investigator-initiated trials for a cheaper and faster way to test new drugs.
“If they’re not doing it, they’re going to lose,” one US CEO told me.
@leileiwu.bsky.social and I have the story for @endpts.com:
endpoints.news/western-gene...
“If they’re not doing it, they’re going to lose,” one US CEO told me.
@leileiwu.bsky.social and I have the story for @endpts.com:
endpoints.news/western-gene...
China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in
IITs have grown increasingly popular among China researchers over the past decade, and have helped China’s fast-growing biotech sector catch up with rivals in the US and Europe. The very leniency that...
endpoints.news
December 15, 2025 at 3:17 PM
Western drugmakers are increasingly turning to Chinese investigator-initiated trials for a cheaper and faster way to test new drugs.
“If they’re not doing it, they’re going to lose,” one US CEO told me.
@leileiwu.bsky.social and I have the story for @endpts.com:
endpoints.news/western-gene...
“If they’re not doing it, they’re going to lose,” one US CEO told me.
@leileiwu.bsky.social and I have the story for @endpts.com:
endpoints.news/western-gene...
Flagship's gene writing startup Tessera Therapeutics strikes $150M partnership with Regeneron for its AATD therapy, which will start clinical trials soon. CRISPR Tx and Prime Medicine are also working on similar therapies for AATD. More details in @endpts.com: endpoints.news/gene-writing...
Gene writing startup Tessera strikes $150M partnership with Regeneron
Regeneron partners with Tessera Therapeutics in $150M deal to develop gene writing therapy for alpha-1 antitrypsin deficiency, expanding its gene editing investments.
endpoints.news
December 1, 2025 at 1:35 PM
Flagship's gene writing startup Tessera Therapeutics strikes $150M partnership with Regeneron for its AATD therapy, which will start clinical trials soon. CRISPR Tx and Prime Medicine are also working on similar therapies for AATD. More details in @endpts.com: endpoints.news/gene-writing...
China biotech Zhongmou Therapeutics has developed an optogenetic gene therapy that uses an engineered alga protein to restore sight, and it hopes the approach could become a ‘one-size-fits-all’ rival to Roche's Luxturna. Read more in @endpts.com: endpoints.news/chinas-zhong...
China biotech seeks to rewire eye cells to create ‘one-size-fits-all’ rival to Luxturna
Wuhan-based Zhongmou Therapeutics reports promising results from gene therapy trial for retinitis pigmentosa, with 7 of 9 blind patients showing vision improvement.
endpoints.news
November 26, 2025 at 4:14 PM
China biotech Zhongmou Therapeutics has developed an optogenetic gene therapy that uses an engineered alga protein to restore sight, and it hopes the approach could become a ‘one-size-fits-all’ rival to Roche's Luxturna. Read more in @endpts.com: endpoints.news/chinas-zhong...
There's been a death in a #CRISPR study, something the field has long feared. A man who was recently hospitalized with liver injury a few weeks after receiving Intellia's experimental gene editing therapy died last night. More details in my story for @endpts.com endpoints.news/patient-in-i...
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.
endpoints.news
November 7, 2025 at 3:46 AM
There's been a death in a #CRISPR study, something the field has long feared. A man who was recently hospitalized with liver injury a few weeks after receiving Intellia's experimental gene editing therapy died last night. More details in my story for @endpts.com endpoints.news/patient-in-i...
Arena BioWorks shuts down after investors pull plug on big bold bet to reinvent biotech, founder Stuart Schreiber confirmed to me. He pointed to biotech macro conditions and also investors seeking bigger returns on AI and tech. Details in my story for @endpts.com: endpoints.news/arena-biowor...
Arena BioWorks shuts down after investors pull plug on bold bid to reinvent biotech model
Arena BioWorks, backed by $500M from billionaires, shuts down after less than 2 years. Founder Stuart Schreiber cites biotech market conditions and investors seeking AI opportunities.
endpoints.news
November 4, 2025 at 11:31 PM
Arena BioWorks shuts down after investors pull plug on big bold bet to reinvent biotech, founder Stuart Schreiber confirmed to me. He pointed to biotech macro conditions and also investors seeking bigger returns on AI and tech. Details in my story for @endpts.com: endpoints.news/arena-biowor...
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
endpoints.news
November 4, 2025 at 1:37 PM
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...
The scientists behind Baby KJ’s life-saving CRISPR therapy have a plan to help more patients. Join me and @drewsnews.bsky.social at 9:45 for a conversation with UPenn's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas to learn more! @endpts.com endpoints.news/post-hoc-liv...
Watch at 9:45 a.m.: Meet the scientists behind Baby KJ’s life-saving CRISPR therapy
U Penn's Musunuru and CHOP's Ahrens-Nicklas discuss plans to expand Baby KJ's custom CRISPR therapy for rare genetic diseases into an FDA-approved treatment.
endpoints.news
October 31, 2025 at 12:59 PM
The scientists behind Baby KJ’s life-saving CRISPR therapy have a plan to help more patients. Join me and @drewsnews.bsky.social at 9:45 for a conversation with UPenn's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas to learn more! @endpts.com endpoints.news/post-hoc-liv...
DNA-chopping enzyme that breaks up NETs (neutrophil extracellular traps) may offer new way to fight autoimmune disease, early data from #Neutrolis suggest. The company has raised $50M from Morningside. Read more in my latest exclusive for @endpts.com. #ACR2025 endpoints.news/dna-chopping...
Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest
Neutrolis tests enzyme therapy targeting neutrophil extracellular traps (NETs) in Phase 1 trial, showing promise for autoimmune diseases. Drug cleared symptoms in teen with DNASE1L3 deficiency.
endpoints.news
October 29, 2025 at 1:41 PM
DNA-chopping enzyme that breaks up NETs (neutrophil extracellular traps) may offer new way to fight autoimmune disease, early data from #Neutrolis suggest. The company has raised $50M from Morningside. Read more in my latest exclusive for @endpts.com. #ACR2025 endpoints.news/dna-chopping...
Causeway Therapeutics had developed a synthetic #microRNA therapy that it hopes will heal injured tendons. The company shared its Phase 2 results with me and its plans to raise a large series A for bigger trials. Read more in my latest story for @endpts.com - endpoints.news/microrna-sta...
Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study
Causeway Therapeutics' microRNA drug for tennis elbow missed primary endpoint in Phase 2, but showed promise in properly injected patients. Plans Phase 3 amid $150M+ fundraising.
endpoints.news
October 27, 2025 at 4:34 PM
Causeway Therapeutics had developed a synthetic #microRNA therapy that it hopes will heal injured tendons. The company shared its Phase 2 results with me and its plans to raise a large series A for bigger trials. Read more in my latest story for @endpts.com - endpoints.news/microrna-sta...
Halda Therapeutics has made small molecule drugs called RIPTACs that inhibit an essential protein cells need to live, but only in the presence of a second protein that is primarily found in cancer cells. My story for @endpts.com on Halda's first clinical data: endpoints.news/halda-reveal...
Halda's first clinical test of RIPTAC drugs suggests a safer way to kill cancer
Halda Therapeutics reports promising data for HLD-0915 in prostate cancer trial, with 59% of patients showing PSA reduction of 50%+ after two treatment cycles.
endpoints.news
October 24, 2025 at 6:35 PM
Halda Therapeutics has made small molecule drugs called RIPTACs that inhibit an essential protein cells need to live, but only in the presence of a second protein that is primarily found in cancer cells. My story for @endpts.com on Halda's first clinical data: endpoints.news/halda-reveal...
Remix Therapeutics has revealed the first clinical data of its "mRNA degrader," a small molecule drug that forces the inclusion of a 'kill switch' into mRNA, leading to its destruction. Its first drug targets the undruggable oncogene MYB. Read more in @endpts.com: endpoints.news/remix-reveal...
Remix Therapeutics reveals first signs of tumor shrinkage with its small molecule mRNA degrader
Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer.
endpoints.news
October 24, 2025 at 2:15 PM
Remix Therapeutics has revealed the first clinical data of its "mRNA degrader," a small molecule drug that forces the inclusion of a 'kill switch' into mRNA, leading to its destruction. Its first drug targets the undruggable oncogene MYB. Read more in @endpts.com: endpoints.news/remix-reveal...
Arcturus announces mixed results of its inhaled #mRNA therapy designed to produce CFTR protein in cystic fibrosis patients.
And the FDA is asking for more data before reviewing its #Covid-19 vaccine for approval.
My story for @endpts.com has the details: endpoints.news/arcturus-ann...
And the FDA is asking for more data before reviewing its #Covid-19 vaccine for approval.
My story for @endpts.com has the details: endpoints.news/arcturus-ann...
Arcturus’ stock halved after mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delay
The biotech's ambitious attempt to restore the critical protein that is broken or missing in people with cystic fibrosis has yielded mixed results in an ongoing Phase 2 study.
endpoints.news
October 22, 2025 at 7:51 PM
Arcturus announces mixed results of its inhaled #mRNA therapy designed to produce CFTR protein in cystic fibrosis patients.
And the FDA is asking for more data before reviewing its #Covid-19 vaccine for approval.
My story for @endpts.com has the details: endpoints.news/arcturus-ann...
And the FDA is asking for more data before reviewing its #Covid-19 vaccine for approval.
My story for @endpts.com has the details: endpoints.news/arcturus-ann...
Starna Therapeutics, a Chinese biotech startup founded by mRNA and LNP scientists, has raised a $44M series B to advance its in vivo CAR-T programs after promising, albeit early, results in lupus and cancer patients. Read more in my exclusive story for @endpts.com: endpoints.news/starna-thera...
Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data
Chinese biotech Starna Therapeutics reports early success in clinical tests of in vivo CAR-T therapy, eliminating B cells in lupus and lymphoma patients, raising $44M Series B from LYFE Capital and ot...
endpoints.news
October 22, 2025 at 2:25 PM
Starna Therapeutics, a Chinese biotech startup founded by mRNA and LNP scientists, has raised a $44M series B to advance its in vivo CAR-T programs after promising, albeit early, results in lupus and cancer patients. Read more in my exclusive story for @endpts.com: endpoints.news/starna-thera...
#CRISPR Therapeutics recently debuted a new gene editing tool called SyNTase editing that it described as 'a significant advance' over prime editing. Prime Medicine disagrees. My latest story for @endpts.com digs into the details: endpoints.news/crispr-thera...
CRISPR Therapeutics says its new gene editing tool is 'a significant advance' over prime editing. Prime Medicine disagrees
CRISPR Therapeutics unveils SyNTase editor tool, plans AATD trial for 2026. Prime Medicine disputes novelty, suggesting similarities to their prime editing tech. Licensing talks reported.
endpoints.news
October 21, 2025 at 1:55 PM
#CRISPR Therapeutics recently debuted a new gene editing tool called SyNTase editing that it described as 'a significant advance' over prime editing. Prime Medicine disagrees. My latest story for @endpts.com digs into the details: endpoints.news/crispr-thera...
British startup Genomics has spent over a decade amassing a human genotype-phenotype database from over 25,000 GWAS studies. Now it is launching a new product to get that data, and software to analyze it, into the hands of drug developers. My story for @endpts.com: endpoints.news/british-star...
British startup Genomics launches business to help drug developers
Oxford spinout Genomics launches Mystra, an AI tool for drug development, using vast genetic database. CEO Peter Donnelly courts pharma leaders from Eli Lilly, Novartis, Roche & Takeda.
endpoints.news
October 16, 2025 at 7:55 PM
British startup Genomics has spent over a decade amassing a human genotype-phenotype database from over 25,000 GWAS studies. Now it is launching a new product to get that data, and software to analyze it, into the hands of drug developers. My story for @endpts.com: endpoints.news/british-star...
Exclusive for @endpts.com: Lipid nanoparticle startup Liberate Bio has emerged with $31M in seed funding from Khosla Ventures and plans to test in vivo cell therapies targeting macrophages and monocytes in the clinic in 2026. endpoints.news/exclusive-li...
Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapies
Liberate Bio raises $31M seed funding from Khosla Ventures, developing in vivo cell therapy using monocytes and macrophages to fight cancer and other diseases.
endpoints.news
October 15, 2025 at 1:41 PM
Exclusive for @endpts.com: Lipid nanoparticle startup Liberate Bio has emerged with $31M in seed funding from Khosla Ventures and plans to test in vivo cell therapies targeting macrophages and monocytes in the clinic in 2026. endpoints.news/exclusive-li...
The Yale spinout Bexorg has raised a $23M series A for its cutting-edge and unconventional approch to preclinical research: testing drugs on ‘rebooted’ human brains from organ donors. My story for @endpts.com has the details: endpoints.news/bexorg-raise...
Yale spinout raises $23M to test drugs on ‘rebooted’ human brains from organ donors
Bexorg has collected $23 million in a Series A raise to scale up its human brain experiments, bringing its total funding to $42.5 million, the startup announced Wednesday.
endpoints.news
October 15, 2025 at 1:25 PM
The Yale spinout Bexorg has raised a $23M series A for its cutting-edge and unconventional approch to preclinical research: testing drugs on ‘rebooted’ human brains from organ donors. My story for @endpts.com has the details: endpoints.news/bexorg-raise...
#ESGCT2025: A woman who was previously ineligible for @genethonfr.bsky.social's Crigler–Najjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in @endpts.com :
endpoints.news/new-study-su...
endpoints.news/new-study-su...
Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way
Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.
endpoints.news
October 10, 2025 at 7:16 PM
#ESGCT2025: A woman who was previously ineligible for @genethonfr.bsky.social's Crigler–Najjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in @endpts.com :
endpoints.news/new-study-su...
endpoints.news/new-study-su...
At #ESGCT2025, Mammoth Bio presented the first monkey data of its lead program, a gene editing therapy that uses its small Cas-Phi enzyme to target APOC3 for triglyceride reduction. A clinical trial is planed for the second half 2026. More in my story for @endpts.com:
endpoints.news/mammoth-bios...
endpoints.news/mammoth-bios...
Mammoth Biosciences is getting closer to finding out if its big bet on tiny CRISPR enzymes will pay off
Mammoth Biosciences reveals monkey data for CRISPR therapy targeting APOC3 gene to lower triglycerides, with CEO Trevor Martin planning clinical trials in 2026.
endpoints.news
October 9, 2025 at 2:31 PM
At #ESGCT2025, Mammoth Bio presented the first monkey data of its lead program, a gene editing therapy that uses its small Cas-Phi enzyme to target APOC3 for triglyceride reduction. A clinical trial is planed for the second half 2026. More in my story for @endpts.com:
endpoints.news/mammoth-bios...
endpoints.news/mammoth-bios...
At #ESGCT2025, Seppo Ylä-Herttuala from the University of Eastern Finland reported success in Phase 2b study of a gene therapy that uses a surgical technique to inject adenoviruses containing the VEGF-D gene into ischemic heart tissue. My story for @endpts.com:
endpoints.news/finnish-rese...
endpoints.news/finnish-rese...
Finnish researchers report success in mid-stage study of heart disease gene therapy
Researchers from the University of Eastern Finland said a gene therapy for people with refractory angina, a form of chronic chest pain that persists despite treatment, was successful in a Phase 2b stu...
endpoints.news
October 9, 2025 at 12:49 PM
At #ESGCT2025, Seppo Ylä-Herttuala from the University of Eastern Finland reported success in Phase 2b study of a gene therapy that uses a surgical technique to inject adenoviruses containing the VEGF-D gene into ischemic heart tissue. My story for @endpts.com:
endpoints.news/finnish-rese...
endpoints.news/finnish-rese...
At #ESGCT2025, the scientists behind Baby KJ’s custom #CRISPR gene editing therapy said they are planning a clinical trial to help more children and turn the one-off drug into an approvable, repeatable procedure. My story for @endpts.com has more details. - endpoints.news/qa-scientist...
Q&A: The scientists behind Baby KJ’s custom CRISPR drug are planning a trial to help more children
Scientists led by Kiran Musunuru plan clinical trial for custom gene editing therapies, following success with
endpoints.news
October 9, 2025 at 10:17 AM
At #ESGCT2025, the scientists behind Baby KJ’s custom #CRISPR gene editing therapy said they are planning a clinical trial to help more children and turn the one-off drug into an approvable, repeatable procedure. My story for @endpts.com has more details. - endpoints.news/qa-scientist...
Arbor Biotechnologies has partnered with Chiesi Group in #CRISPR gene editing deal worth up to $2 billion, just 10 weeks after announcing it had dosed the first patient in its PH1 trial. Next up for Arbor: a trio of ALS therapies. Read more in @endpts.com - endpoints.news/arbor-partne...
Arbor partners with Chiesi Group in gene editing deal with potential $2B future payments
Chiesi Group partners with Arbor Biotechnologies in CRISPR deal worth up to $2B for PH1 therapy and rare liver diseases, following first patient dosing in clinical trial.
endpoints.news
October 6, 2025 at 6:52 PM
Arbor Biotechnologies has partnered with Chiesi Group in #CRISPR gene editing deal worth up to $2 billion, just 10 weeks after announcing it had dosed the first patient in its PH1 trial. Next up for Arbor: a trio of ALS therapies. Read more in @endpts.com - endpoints.news/arbor-partne...